CN117551103A - 作为btk抑制剂的吡咯并嘧啶类化合物及其应用 - Google Patents

作为btk抑制剂的吡咯并嘧啶类化合物及其应用 Download PDF

Info

Publication number
CN117551103A
CN117551103A CN202311079865.7A CN202311079865A CN117551103A CN 117551103 A CN117551103 A CN 117551103A CN 202311079865 A CN202311079865 A CN 202311079865A CN 117551103 A CN117551103 A CN 117551103A
Authority
CN
China
Prior art keywords
compound
added
mmol
synthesis
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN202311079865.7A
Other languages
English (en)
Chinese (zh)
Inventor
张杨
伍文韬
耿开骏
李秋
黎健
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Longchuan Biomedical Technology Co ltd
Original Assignee
Zhejiang Longchuan Biomedical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Longchuan Biomedical Technology Co ltd filed Critical Zhejiang Longchuan Biomedical Technology Co ltd
Publication of CN117551103A publication Critical patent/CN117551103A/zh
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202311079865.7A 2019-11-13 2020-11-13 作为btk抑制剂的吡咯并嘧啶类化合物及其应用 Withdrawn CN117551103A (zh)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
CN201911109773 2019-11-13
CN2019111097732 2019-11-13
CN2019112884928 2019-12-13
CN201911288492 2019-12-13
CN202010096582 2020-02-17
CN2020100965823 2020-02-17
CN202010711270 2020-07-22
CN2020107112709 2020-07-22
CN202080078768.4A CN114728974B (zh) 2019-11-13 2020-11-13 作为btk抑制剂的吡咯并嘧啶类化合物及其应用
PCT/CN2020/128597 WO2021093839A1 (zh) 2019-11-13 2020-11-13 作为btk抑制剂的吡咯并嘧啶类化合物及其应用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202080078768.4A Division CN114728974B (zh) 2019-11-13 2020-11-13 作为btk抑制剂的吡咯并嘧啶类化合物及其应用

Publications (1)

Publication Number Publication Date
CN117551103A true CN117551103A (zh) 2024-02-13

Family

ID=75912541

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202311079865.7A Withdrawn CN117551103A (zh) 2019-11-13 2020-11-13 作为btk抑制剂的吡咯并嘧啶类化合物及其应用
CN202080078768.4A Active CN114728974B (zh) 2019-11-13 2020-11-13 作为btk抑制剂的吡咯并嘧啶类化合物及其应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202080078768.4A Active CN114728974B (zh) 2019-11-13 2020-11-13 作为btk抑制剂的吡咯并嘧啶类化合物及其应用

Country Status (6)

Country Link
US (1) US12378253B2 (https=)
EP (1) EP4059935A4 (https=)
JP (1) JP7473642B2 (https=)
KR (1) KR102793446B1 (https=)
CN (2) CN117551103A (https=)
WO (1) WO2021093839A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4234558A4 (en) * 2020-12-07 2024-10-23 Zhejiang Longcharm Bio-Tech Pharma. Co., Ltd. PYRROLOPYRIDINE COMPOUND AND APPLICATION THEREOF
WO2022213932A1 (zh) * 2021-04-06 2022-10-13 广州必贝特医药股份有限公司 吡咯并嘧啶酮类化合物及其应用
CN114761410B (zh) * 2021-04-06 2023-08-25 广州必贝特医药股份有限公司 吡咯并嘧啶酮类化合物及其应用
EP4339198A4 (en) * 2021-05-12 2025-06-11 Zhejiang Longcharm Bio-Tech Pharma. Co., Ltd. CRYSTAL FORM OF A PYRROLOPYRIMIDINE COMPOUND AND METHOD FOR PREPARING THE CRYSTAL FORM
KR20240157639A (ko) 2021-12-14 2024-11-01 크로스파이어 온콜로지 홀딩 비.브이. 거대고리 btk 억제제
CN115894500B (zh) * 2022-11-02 2024-05-28 中国药科大学 一种作为btk激酶抑制剂的化合物及其制备方法与用途
CN118702697A (zh) * 2023-03-18 2024-09-27 山东新时代药业有限公司 苯甲酰基吡咯并嘧啶类衍生物及其用途和制备方法
CN116375715B (zh) * 2023-04-06 2025-04-04 中国药科大学 一种作为非共价btk激酶抑制剂的化合物及其生物用途
WO2024245578A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a macrocyclic reversible btk inhibitor
WO2024245577A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a reversible btk inhibitor
WO2024246287A1 (en) 2023-06-02 2024-12-05 Crossfire Oncology Holding B.V. Medical use of a macrocyclic reversible btk inhibitor
WO2024256568A1 (en) 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Salt and crystal forms of a macrocyclic btk inhibitor
WO2024256574A1 (en) 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Process for preparing macrocyclic btk inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI398252B (zh) * 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
EP3170825B1 (en) * 2012-08-06 2019-04-10 ACEA Biosciences Inc. Novel pyrrolopyrimidine compounds as inhibitors of protein kinases
EP3042903B1 (en) * 2015-01-06 2019-08-14 Impetis Biosciences Ltd. Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
SI3882250T1 (sl) * 2015-12-23 2023-07-31 Arqule, Inc. Tetrahidropiranil amino-pirolopirimidinon za uporabo pri zdravljenju z BTK posredovanih motenj
TW201811795A (zh) * 2016-08-24 2018-04-01 美商亞闊股份有限公司 胺基－吡咯并嘧啶酮化合物及其用途

Also Published As

Publication number Publication date
EP4059935A1 (en) 2022-09-21
JP7473642B2 (ja) 2024-04-23
KR102793446B1 (ko) 2025-04-09
CN114728974A (zh) 2022-07-08
KR20220097455A (ko) 2022-07-07
EP4059935A4 (en) 2024-02-28
JP2023506691A (ja) 2023-02-20
US20230357248A1 (en) 2023-11-09
CN114728974B (zh) 2023-09-19
WO2021093839A1 (zh) 2021-05-20
US12378253B2 (en) 2025-08-05

Similar Documents

Publication Publication Date Title
CN117551103A (zh) 作为btk抑制剂的吡咯并嘧啶类化合物及其应用
CN113121530B (zh) 作为krasg12c突变蛋白抑制剂的吡啶酮并嘧啶类衍生物
JP7168149B2 (ja) Ｆｇｆｒ阻害剤としてのピラジン－２（１ｈ）－オン系化合物
CN113993860B (zh) 作为kras g12c突变蛋白抑制剂的七元杂环类衍生物
WO2020035065A1 (zh) 作为ret抑制剂的吡唑衍生物
WO2020200316A1 (zh) 作为ret抑制剂的吡唑并吡啶类化合物及其应用
CN109790148A (zh) 具有usp30抑制剂活性的氰基取代的杂环
CN114761407A (zh) 作为高选择性ros1抑制剂的化合物及其应用
JP2022540360A (ja) Ｄｎａ－ｐｋ阻害剤としてのキノリン及びシンノリン誘導体
CN116249698A (zh) 异色满类化合物
WO2021129817A1 (zh) 具有果糖激酶(khk)抑制作用的嘧啶类化合物
CN114008046B (zh) 作为cdk9抑制剂的氮杂吲哚连吡唑类化合物
CN112752749B (zh) 作为pd-l1免疫调节剂的氟乙烯基苯甲酰胺基化合物
WO2020156564A1 (zh) 作为pd-l1免疫调节剂的乙烯基吡啶甲酰胺基化合物
CN113811530B (zh) 作为糜酶抑制剂的嘧啶酮类化合物及其应用
CN116438175B (zh) 苯并脲环衍生物及其制备方法和应用
WO2022199635A1 (zh) 苄氨基喹唑啉类衍生物
WO2022253335A1 (zh) 含磺酰基的芳基类化合物及其应用
CN117279923A (zh) 六元杂芳并脲环的衍生物及其应用
WO2021139814A1 (zh) 喹啉并咪唑类化合物及其应用
HK40080199A (en) Pyrrolopyrimidine compound as btk inhibitor and use thereof
RU2789450C1 (ru) Фторвинилбензамидное соединение в качестве иммуномодулятора PD-L1
CN118139865A (zh) 吡咯并吡唑螺环化合物
CN116490504A (zh) 吡咯并吡啶类化合物及其应用
TW202317094A (zh) 嘧啶三並環衍生物及其在藥學上的應用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20240213